Uno studio sulla persistenza del trattamento con Guselkumab nei partecipanti con artrite psoriasica (PEGASUS)
Uno studio prospettico reale sulla persistenza del trattamento con Guselkumab in pazienti con artrite psoriasica
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Lille, Francia, 59037
- Reclutamento
- Hopital Roger Salengro - CHU Lille
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study population will include participants affected with psoriatic arthritis (PsA) according to classification for psoriatic arthritis (CASPAR) criteria.
Descrizione
Inclusion criteria:
- Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
- Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study
- Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
- The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
- Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements
Exclusion Criteria:
- Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.
- Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase [JAK] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time
- Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)
- Unwilling or unable to participate in long-term data collection
- Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)
- Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study
- Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
Group 1: Psoriatic Arthritis Participants Treated With Guselkumab
Participants with confirmed diagnosis of psoriatic arthritis treated with guselkumab as per routine clinical practice will be enrolled. No drug will be provided as part of this study. Only data available within routine clinical practice will be collected in this study. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Participants Still Receiving Treatment at 1 Year
Lasso di tempo: At 1 year
|
Discontinuation or maintenance of guselkumab treatment will be recorded by the physician at each visit. Proportion of participants still receiving treatment will be reported in the outcome measure. |
At 1 year
|
|
Percentage of Participants Still Receiving Treatment at Persistence Time
Lasso di tempo: Up to 8 weeks
|
Persistence time of the initial treatment: defined as the time from the date of the first administration of guselkumab to the date that the last dose of guselkumab treatment was administered plus 1 dosing interval (8 weeks), or until start of subsequent treatment. |
Up to 8 weeks
|
|
Number of Participants Starting New Treatment
Lasso di tempo: At 1 year
|
Participants starting new treatment along with reason of discontinuation will be reported. |
At 1 year
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants Still Receiving Treatment at 2 years
Lasso di tempo: At 2 years
|
Percentage of participants still receiving treatment at 2 years will be reported. |
At 2 years
|
|
Percentage of Participants Discontinuing The Treatment
Lasso di tempo: At 2 years
|
Participants discontinuing the treatment along with the reasons will be reported. |
At 2 years
|
|
Change From Baseline in Disease Activity Index in Psoriatic Arthritis (DAPSA)/ Clinical Disease Activity Index in Psoriatic Arthritis (cDAPSA)
Lasso di tempo: Baseline, Months 3,6,12,18, and 24
|
The DAPSA was developed to characterize psoriatic arthritis (PsA) disease activity. It considers the number of painful and swollen joints, the patient's assessment of their disease and the C-reactive protein (CRP) measurement for acute inflammation. Where CRP measurements are not available, the clinical DAPSA (cDAPSA) maybe be used, which omits CRP. An overall score is calculated, where higher scores correspond to higher disease activity. Cut-off values for DAPSA low and high disease activity are: ≤14 and >28 points, respectively, and for remission is ≤4 points. The cut-off values for cDAPSA are: ≤4 points for remission, >4 to ≤13 points for low disease activity, > 13 to ≤27 points for moderate disease activity, and >27 points for high disease activity. |
Baseline, Months 3,6,12,18, and 24
|
|
Change From Baseline in Leeds Enthesitis Index (LEI) Score
Lasso di tempo: Baseline, Months 3,6,12,18, and 24
|
The Leeds enthesitis index (LEI) measures the activity of enthesitis in PsA. The index measures the severity and activity of enthesitis, inflammation at the attachment of the ligaments and tendons to bone. The clinical assessor must elicit tenderness at 6 enthesitis sites: both lateral epicondyles of the humerus, both medial condyles of the femur, and the Achilles tendon insertions. Each site affected is summed to give a score out of 6, where 6 indicates all sites affected. |
Baseline, Months 3,6,12,18, and 24
|
|
Change From Baseline in Back and Neck Pain Numerical Rating Scale (NRS) Score
Lasso di tempo: Baseline, Months 3,6,12,18, and 24
|
NRS for back and neck pain will be administered. This is a simple numbered 0-10 scale on which the patient indicates the intensity of their pain (0 represents no pain and 10 indicates the worst possible pain). |
Baseline, Months 3,6,12,18, and 24
|
|
Hazard Ratios Between Baseline Clinical Factors and Guselkumab Persistence and Effectiveness at Months 12 and 24
Lasso di tempo: At Month 12 and 24
|
Hazard ratios for association between baseline clinical factors and persistence/effectiveness from Cox proportional hazards models will be reported. |
At Month 12 and 24
|
|
Sociodemographic Characteristics: Age
Lasso di tempo: At Baseline
|
Participant's age will be reported. |
At Baseline
|
|
Sociodemographic Characteristics: Sex
Lasso di tempo: At Baseline
|
Participant's sex (male, female) will be reported |
At Baseline
|
|
Sociodemographic Characteristics: Weight
Lasso di tempo: At Baseline
|
Participant's weight will be reported |
At Baseline
|
|
Sociodemographic Characteristics: Height
Lasso di tempo: At Baseline
|
Participant's height will be reported. |
At Baseline
|
|
Sociodemographic Characteristics: Body Mass Index (BMI)
Lasso di tempo: At Baseline
|
Participant's BMI will be reported. |
At Baseline
|
|
Number of Participants Reporting Smoking, Cannabis and Alcohol Use
Lasso di tempo: At Baseline
|
Participant's smoking, use of Cannabis and Alcohol habit will be reported. |
At Baseline
|
|
Number of Participants With Family History of Psoriasis and/or Psoriatic Arthritis and/or Spondyloarthritis
Lasso di tempo: At Baseline
|
Family history of psoriasis and/or psoriatic arthritis and/or spondyloarthritis wil be reported. |
At Baseline
|
|
Date of Diagnosis of Psoriatic Arthritis
Lasso di tempo: At Baseline
|
Date of diagnosis of psoriatic arthritis will be reported. |
At Baseline
|
|
Date of Previous Treatments of Psoriatic Arthritis
Lasso di tempo: At Baseline
|
Date of previous treatments of psoriatic arthritis will be reported. |
At Baseline
|
|
Duration of Previous Treatments of Psoriatic Arthritis
Lasso di tempo: At Baseline
|
Duration of previous treatments of psoriatic arthritis will be reported. |
At Baseline
|
|
Medical History and Current Situation
Lasso di tempo: At Baseline
|
Participants medical history and current medical situation will be reported. |
At Baseline
|
|
Number of Participants Receiving Co-occurring Treatments Linked to Psoriatic Arthritis
Lasso di tempo: Baseline up to 2 Years
|
Participants receiving co-occurring treatments linked to psoriatic arthritis at baseline and during follow-up will be reported. |
Baseline up to 2 Years
|
|
Failure to Achieve or Maintain Response
Lasso di tempo: Up to 2 Years
|
Failure to achieve or maintain response to at least 2 biologic/targeted synthetic DMARDs with at least 2 different mechanisms of action (Y/N) (For treatment refractory criteria). |
Up to 2 Years
|
|
Number of Participants Reporting Problems Related to the Management of Signs and Symptoms
Lasso di tempo: At baseline
|
The management of signs and/or symptoms that is perceived as problematic by the rheumatologist and/or the participants will be reported. |
At baseline
|
|
Evidence of Persistent Disease
Lasso di tempo: Up to 2 Years
|
Evidence of persistent disease as defined by at least 2 of the following: a) failure to achieve or maintain low disease activity, b) the presence of active extra-musculoskeletal manifestations of PsA, c) objective evidence of inflammatory activity, namely clinical signs, elevated acute phase reactants and/or imaging findings suggestive of inflammation. |
Up to 2 Years
|
|
Number of Participants with Co-Morbidities
Lasso di tempo: At baseline
|
Number of participants with co-morbidities will be reported. |
At baseline
|
|
Number of Participants with Abnormal Psychosocial Factors
Lasso di tempo: At Baseline
|
Number of participants with abnormal psychosocial factors will be reported. |
At Baseline
|
|
Healthcare Professional (HCP): Age Group
Lasso di tempo: At Baseline
|
Age group of HCP will be reported. |
At Baseline
|
|
HCP: Sex
Lasso di tempo: At Baseline
|
Sex of HCP will be reported. |
At Baseline
|
|
HCP: Experience
Lasso di tempo: At Baseline
|
Experience of HCP will be reported. |
At Baseline
|
|
HCP: Type of Practice
Lasso di tempo: At Baseline
|
Type of practice of HCP will be reported. |
At Baseline
|
|
Number of Participants With Adverse Events, Serious Adverse Events, Infections and Injection Site Reactions
Lasso di tempo: Up to 2 Years
|
AEs with onset or worsening on or after date of first dose of study treatment. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1 equal (=) Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to AE. SAE is any untoward medical occurrence that results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Up to 2 Years
|
|
Tolerance Related Guselkumab Treatment
Lasso di tempo: Up to 2 Years
|
Tolerance Related guselkumab treatment will be reported. |
Up to 2 Years
|
|
Dose at Initiation of Guselkumab
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Dose at initiation of guselkumab will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Treatment Interval at Initiation of Guselkumab
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Treatment interval at initiation of guselkumab will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Type of Injection
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Type of injection will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Number of Participants Reporting Change of Injection Frequency
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Participants reporting change of injection frequency (Q4 to Q8 or Q8 to Q4) and its reason will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Number of Participant With Co-occurring Treatments Linked to PSA
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Participants with co-occurring treatments linked to PSA will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Number of Participants With Reason for Choosing Guselkumab From the Therapeutic Arsenal
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Participants with reason for choosing guselkumab from the therapeutic arsenal will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Number of Participants Switching to New Treatment in Case of Discontinuation of Guselkumab Treatment
Lasso di tempo: At Months 0, 3, 6, 12, 18 and 24
|
Participants switching to new treatment in case of discontinuation of guselkumab treatment will be reported. |
At Months 0, 3, 6, 12, 18 and 24
|
|
Change From Baseline in 12-item Psoriatic Arthritis Impact of Disease Questionnaire (PsAID-12) Questionnaire Score
Lasso di tempo: Baseline, Months 0, 3, 6, 12, 18 and 24
|
The PsAID-12 questionnaire was designed to assess the impact of disease, with questions on pain, physical function, fatigue, coping and depression. It is a validated, self-administered questionnaire developed for use in clinical practice that assesses the impact of PsA on patients' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly). |
Baseline, Months 0, 3, 6, 12, 18 and 24
|
|
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Each Visit After Baseline
Lasso di tempo: Baseline, Months 0, 3, 6, 12, 18 and 24
|
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was developed to measure disease activity in patients with ankylosing spondylitis. It consists of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration and morning stiffness severity. Each symptom is assessed on a scale of 0-10 where 0 indicates no pain or discomfort and 10 indicates maximum pain or discomfort. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease. |
Baseline, Months 0, 3, 6, 12, 18 and 24
|
|
Satisfaction of Treatment for the Participants
Lasso di tempo: At Months 3, 6, 12, 18 and 24
|
The satisfaction of treatment for the participant will be assessed using a 5-point Likert scale, ("Very dissatisfied Dissatisfied Neither satisfied nor dissatisfied Satisfied Very satisfied"). The scale includes two patient reported questions: "1) How satisfied or dissatisfied are you with the overall convenience of this medication" and "2) How satisfied or dissatisfied are you with the ability of this medication ability to treat your condition?" Scores range from Very dissatisfied to Very satisfied and will be used to evaluate satisfaction with guselkumab treatment. |
At Months 3, 6, 12, 18 and 24
|
|
Satisfaction of Treatment Care Management and Patient Relationship for the Rheumatologist
Lasso di tempo: At Months 3, 6, 12, 18 and 24
|
Satisfaction of treatment care management and patient relationship for the rheumatologist will be assessed using a 5-point Likert scale specified as : "Very dissatisfied, Dissatisfied, Neither satisfied nor dissatisfied, Satisfied and Very satisfied." The physician-reported questions are: "1) How satisfied or dissatisfied are you with this drug overall for this patient?" and "2) How satisfied or dissatisfied are you with the ease of managing your patient with guselkumab?" |
At Months 3, 6, 12, 18 and 24
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Janssen-Cilag France Clinical Trial, Janssen-Cilag France
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CNTO1959PSA4021
- CNTO1959PSA4021 (Altro identificatore: Janssen Research & Development, LLC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .